Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The enzyme adenosine deaminase (ADA) is a multifunctional protein that can both degrade adenosine and bind extracellularly to adenosine receptors, acting as an allosteric modulator regulating the hormonal effects of adenosine. The molecular regions of ADA responsible for the latter are unknown. In this work, alanine scanning mutagenesis of various ADA amino acid stretches, selected through in silico docking experiments, allowed us to identify regions of the enzyme responsible for modulating both its catalytic activity and its ability to modulate agonist binding to A and A adenosine receptors (AR and AR). The combination of computational and in vitro experiments show that the structural gate to the catalytic site; i.e., the α-1 helix containing residues L58-I72 and the loop containing residues A184-I188 of ADA, were important to maintain both the catalytic efficiency of the enzyme and its action as an allosteric modulator of the adenosine receptors. These data are consistent with a predicted supramolecular assembly, in which ADA bridges AR and CD26 and are in line with the notion that the interaction of ADA with adenosine receptors has an important role in the immunosynapse. We propose that it is the ADA open form, but not the closed one, that is responsible for the functional interaction with A₁R and A₂AR.

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.12-212621DOI Listing

Publication Analysis

Top Keywords

adenosine receptors
20
adenosine
9
catalytic site
8
structural gate
8
adenosine deaminase
8
binding adenosine
8
allosteric modulator
8
ada
7
receptors
5
catalytic
4

Similar Publications

This study investigates the potential protective effects of eugenol on cecal ligation puncture (CLP) induced sepsis rat model. CLP was used to induce sepsis in rats and then treated with eugenol at doses of 25 and 50 mg/kg, i.p.

View Article and Find Full Text PDF

Adenosine A receptors (AARs) have shown promising therapeutic properties despite their controversial role in modulating stroke outcome. However, the temporal evolution of cerebral AARs density after cerebral ischemia and its subsequent neuroinflammatory response have been scarcely explored. In this study, the expression of AARs after transient middle cerebral artery occlusion (MCAO) was evaluated in rats by positron emission tomography (PET) with [C]SCH442416 and immunohistochemistry (IHC).

View Article and Find Full Text PDF

Cancer immunotherapy represents a transformative strategy in modern oncology, utilizing the body's immune system to recognize and eliminate malignant cells with precision. Unlike traditional therapies, which often directly target the tumor, immunotherapy enhances the immune system's inherent ability to differentiate between healthy and cancerous cells. The advent of immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 and CTLA-4 pathways, has marked a significant breakthrough in this field.

View Article and Find Full Text PDF

β-Glucan, a polysaccharide from Saccharomyces cerevisiae with immunomodulatory activities that may not trigger pro-inflammatory responses in microglia, has been reported to show rapid antidepressant effects in chronically stressed animals by restoring microglial function in the dentate gyrus. However, the mechanisms underlying this effect of β-glucan are still largely unclear. Considering the importance of astrocytic purinergic 2Y1 receptors (P2Y1Rs) and brain-derived neurotrophic factor (BDNF) in the antidepressant effects of microglial stimulation, we hypothesize that β-glucan produces antidepressant effects by mobilizing astrocytic P2Y1R-triggered BDNF signaling in the hippocampus.

View Article and Find Full Text PDF

Diabetes mellitus is a common and serious metabolic disease globally, characterized by increased blood glucose levels. The major pathogenesis is the functional impairment of insulin-producing beta cells in the pancreas and the lack of insulin secretion. Although both type 1 and type 2 diabetes develop through distinct pathological mechanisms, they lead to the destruction and/or dysfunction of beta cells, resulting in inadequate beta cell mass to maintain normal blood glucose levels.

View Article and Find Full Text PDF